![]() |
|
|
Vol. 295, Issue 1, 91-99, October 2000
School of Pharmacy, The University of Queensland, St. Lucia,
Queensland, Australia
Our previous studies indicate that oxycodone is a putative
-opioid
agonist, whereas morphine is a well documented µ-opioid agonist.
Because there is limited information regarding the development of
tolerance to oxycodone, this study was designed to 1) document the
development of tolerance to the antinociceptive effects of chronically
infused i.v. oxycodone relative to that for i.v. morphine and 2)
quantify the degree of antinociceptive cross-tolerance between morphine
and oxycodone in adult male Dark Agouti (DA) rats. Antinociceptive
testing was performed using the tail-flick latency test. Complete
antinociceptive tolerance was achieved in 48 to 84 h after chronic
infusion of equi-antinociceptive doses of i.v. oxycodone (2.5 mg/24 h
and 5 mg/24 h) and i.v. morphine (10 mg/24 h and 20 mg/24 h,
respectively). Dose-response curves for bolus doses of i.v. and i.c.v.
morphine and oxycodone were produced in naive, morphine-tolerant, and
oxycodone-tolerant rats. Consistent with our previous findings that
oxycodone and morphine produce their intrinsic antinociceptive effects
through distinctly different opioid receptor populations, there was no
discernible cross-tolerance when i.c.v. oxycodone was given to
morphine-tolerant rats. Similarly, only a low degree of cross-tolerance
(
24%) was observed after i.v. oxycodone administration to
morphine-tolerant rats. By contrast, both i.v. and i.c.v. morphine
showed a high degree of cross-tolerance (
71% and
54%,
respectively) in rats rendered tolerant to oxycodone. Taken together,
these findings suggest that, after parenteral but not supraspinal
administration, oxycodone is metabolized to a µ-opioid agonist
metabolite, thereby explaining asymmetric and incomplete
cross-tolerance between oxycodone and morphine.
This article has been cited by other articles:
![]() |
S. P. Hume, A. R. Lingford-Hughes, V. Nataf, E. Hirani, R. Ahmad, A. N. Davies, and D. J. Nutt Low Sensitivity of the Positron Emission Tomography Ligand [11C]Diprenorphine to Agonist Opiates J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 661 - 667. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Karunatilake and N. A Buckley Serotonin Syndrome Induced by Fluvoxamine and Oxycodone Ann. Pharmacother., January 1, 2006; 40(1): 155 - 157. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Cook and M. D. Nickerson Nociceptive Sensitivity and Opioid Antinociception and Antihyperalgesia in Freund's Adjuvant-Induced Arthritic Male and Female Rats J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 449 - 459. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Bolan, R. J. Tallarida, and G. W. Pasternak Synergy between {micro} Opioid Ligands: Evidence for Functional Interactions among {micro} Opioid Receptor Subtypes J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 557 - 562. [Abstract] [Full Text] [PDF] |
||||